-transparent.png){kind=logo}
Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis. 2023
Joan Carles, and
Rafael A Medina-Lopez, and
Javier Puente, and
Álvaro Gómez-Ferrer, and
Javier Casas Nebra, and
María Isabel Sáez Medina, and
Maria J Ribal, and
Alfredo Rodríguez Antolín, and
José Luís Álvarez-Ossorio, and
José Francisco Suárez Novo, and
Cristina Moretones Agut, and
Shankar Srinivasan, and
Jorge Ortiz, and
Karim Fizazi
Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Aim: Darolutamide significantly prolonged metastasis-free survival (MFS) versus placebo in the Phase III ARAMIS study. We analyzed outcomes in Spanish participants in ARAMIS. Patients & methods: Patients with high-risk nonmetastatic castration-resistant prostate cancer were randomized 2:1 to darolutamide 600 mg twice daily or placebo, plus androgen-deprivation therapy. The primary end point was MFS. Descriptive statistics are reported for this post hoc analysis. Results: In Spanish participants, darolutamide (n = 75) prolonged MFS versus placebo (n = 42): hazard ratio 0.345, 95% confidence interval 0.175-0.681. The incidence and type of treatment-emergent adverse events were comparable between treatment arms. Conclusion: For Spanish participants in ARAMIS, efficacy outcomes favored darolutamide versus placebo, with a similar safety profile, consistent with the overall ARAMIS population. Clinical Trials Registration: NCT02200614 (ClinicalTrials.gov).
Related Publications
Joan Carles, and
Rafael A Medina-Lopez, and
Javier Puente, and
Álvaro Gómez-Ferrer, and
Javier Casas Nebra, and
María Isabel Sáez Medina, and
Maria J Ribal, and
Alfredo Rodríguez Antolín, and
José Luís Álvarez-Ossorio, and
José Francisco Suárez Novo, and
Cristina Moretones Agut, and
Shankar Srinivasan, and
Jorge Ortiz, and
Karim Fizazi
March 2019,
The New England journal of medicine,
Joan Carles, and
Rafael A Medina-Lopez, and
Javier Puente, and
Álvaro Gómez-Ferrer, and
Javier Casas Nebra, and
María Isabel Sáez Medina, and
Maria J Ribal, and
Alfredo Rodríguez Antolín, and
José Luís Álvarez-Ossorio, and
José Francisco Suárez Novo, and
Cristina Moretones Agut, and
Shankar Srinivasan, and
Jorge Ortiz, and
Karim Fizazi
September 2022,
The New England journal of medicine,
Joan Carles, and
Rafael A Medina-Lopez, and
Javier Puente, and
Álvaro Gómez-Ferrer, and
Javier Casas Nebra, and
María Isabel Sáez Medina, and
Maria J Ribal, and
Alfredo Rodríguez Antolín, and
José Luís Álvarez-Ossorio, and
José Francisco Suárez Novo, and
Cristina Moretones Agut, and
Shankar Srinivasan, and
Jorge Ortiz, and
Karim Fizazi
October 2019,
The Journal of urology,
Joan Carles, and
Rafael A Medina-Lopez, and
Javier Puente, and
Álvaro Gómez-Ferrer, and
Javier Casas Nebra, and
María Isabel Sáez Medina, and
Maria J Ribal, and
Alfredo Rodríguez Antolín, and
José Luís Álvarez-Ossorio, and
José Francisco Suárez Novo, and
Cristina Moretones Agut, and
Shankar Srinivasan, and
Jorge Ortiz, and
Karim Fizazi
October 2019,
European urology,
Joan Carles, and
Rafael A Medina-Lopez, and
Javier Puente, and
Álvaro Gómez-Ferrer, and
Javier Casas Nebra, and
María Isabel Sáez Medina, and
Maria J Ribal, and
Alfredo Rodríguez Antolín, and
José Luís Álvarez-Ossorio, and
José Francisco Suárez Novo, and
Cristina Moretones Agut, and
Shankar Srinivasan, and
Jorge Ortiz, and
Karim Fizazi
May 2021,
Future oncology (London, England),
Joan Carles, and
Rafael A Medina-Lopez, and
Javier Puente, and
Álvaro Gómez-Ferrer, and
Javier Casas Nebra, and
María Isabel Sáez Medina, and
Maria J Ribal, and
Alfredo Rodríguez Antolín, and
José Luís Álvarez-Ossorio, and
José Francisco Suárez Novo, and
Cristina Moretones Agut, and
Shankar Srinivasan, and
Jorge Ortiz, and
Karim Fizazi
September 2020,
The New England journal of medicine,
Joan Carles, and
Rafael A Medina-Lopez, and
Javier Puente, and
Álvaro Gómez-Ferrer, and
Javier Casas Nebra, and
María Isabel Sáez Medina, and
Maria J Ribal, and
Alfredo Rodríguez Antolín, and
José Luís Álvarez-Ossorio, and
José Francisco Suárez Novo, and
Cristina Moretones Agut, and
Shankar Srinivasan, and
Jorge Ortiz, and
Karim Fizazi
January 2021,
Indian journal of urology : IJU : journal of the Urological Society of India,
Joan Carles, and
Rafael A Medina-Lopez, and
Javier Puente, and
Álvaro Gómez-Ferrer, and
Javier Casas Nebra, and
María Isabel Sáez Medina, and
Maria J Ribal, and
Alfredo Rodríguez Antolín, and
José Luís Álvarez-Ossorio, and
José Francisco Suárez Novo, and
Cristina Moretones Agut, and
Shankar Srinivasan, and
Jorge Ortiz, and
Karim Fizazi
March 2023,
European urology,
Joan Carles, and
Rafael A Medina-Lopez, and
Javier Puente, and
Álvaro Gómez-Ferrer, and
Javier Casas Nebra, and
María Isabel Sáez Medina, and
Maria J Ribal, and
Alfredo Rodríguez Antolín, and
José Luís Álvarez-Ossorio, and
José Francisco Suárez Novo, and
Cristina Moretones Agut, and
Shankar Srinivasan, and
Jorge Ortiz, and
Karim Fizazi
March 2021,
International journal of clinical oncology,
Joan Carles, and
Rafael A Medina-Lopez, and
Javier Puente, and
Álvaro Gómez-Ferrer, and
Javier Casas Nebra, and
María Isabel Sáez Medina, and
Maria J Ribal, and
Alfredo Rodríguez Antolín, and
José Luís Álvarez-Ossorio, and
José Francisco Suárez Novo, and
Cristina Moretones Agut, and
Shankar Srinivasan, and
Jorge Ortiz, and
Karim Fizazi
February 2024,
The oncologist,
